These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
137 related items for PubMed ID: 6148775
21. Epidermal growth factor enhances guanylate cyclase activity in vivo and in vitro. Scheving LA, Scheving LE, Tsai TH, Vesely DL. Endocrinology; 1985 Jan; 116(1):332-6. PubMed ID: 2856873 [Abstract] [Full Text] [Related]
22. Benzodifuroxan as an NO-dependent activator of soluble guanylate cyclase and a novel highly effective inhibitor of platelet aggregation. Bussygina OG, Pyatakova NV, Khropov YV, Ovchinnikov IV, Makhova NN, Severina IS. Biochemistry (Mosc); 2000 Apr; 65(4):457-62. PubMed ID: 10810184 [Abstract] [Full Text] [Related]
23. Increased responsiveness of the hepatic guanylate cyclase-guanosine 3',5'-monophosphate system to nitrosoguanidine following partial hepatectomy. Briggs RG, Derubertis FR. Biochim Biophys Acta; 1980 Apr 03; 628(4):425-37. PubMed ID: 6102869 [Abstract] [Full Text] [Related]
24. The interrelationship of somatostatin and guanylate cyclase activity. Vesely DL. Mol Cell Biochem; 1980 Nov 20; 32(3):131-4. PubMed ID: 6110170 [Abstract] [Full Text] [Related]
25. [Soluble platelet guanylate cyclase: significance of heme in regulating enzymatic activity and the role of the enzyme in platelet aggregation]. Severina IS. Biokhimiia; 1994 Mar 20; 59(3):325-39. PubMed ID: 7910045 [Abstract] [Full Text] [Related]
26. Quercetin, a phytoestrogen and dietary flavonoid, activates different membrane-bound guanylate cyclase isoforms in LLC-PK1 and PC12 cells. Chen ZJ, Vetter M, Chang GD, Liu S, Chang CH. J Pharm Pharmacol; 2003 Mar 20; 55(3):353-8. PubMed ID: 12724041 [Abstract] [Full Text] [Related]
27. Biochemical evidence of cocarcinogenesis: tumor promoting agent enhances methylnitrosourea activation of rat guanylate cyclase activity. Vesely DL. Res Commun Chem Pathol Pharmacol; 1979 May 20; 24(2):329-38. PubMed ID: 37562 [Abstract] [Full Text] [Related]
37. Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase. Olesen SP, Drejer J, Axelsson O, Moldt P, Bang L, Nielsen-Kudsk JE, Busse R, Mülsch A. Br J Pharmacol; 1998 Jan 20; 123(2):299-309. PubMed ID: 9489619 [Abstract] [Full Text] [Related]
38. Nitric oxide-dependent reduction in soluble guanylate cyclase functionality accounts for early lipopolysaccharide-induced changes in vascular reactivity. Fernandes D, da Silva-Santos JE, Duma D, Villela CG, Barja-Fidalgo C, Assreuy J. Mol Pharmacol; 2006 Mar 20; 69(3):983-90. PubMed ID: 16326931 [Abstract] [Full Text] [Related]
39. Guanylin activates rat colonic particulate guanylate cyclase. Khare S, Wilson D, Wali RK, Tien XY, Bissonnette M, Niedziela SM, Bolt MJ, Sitrin MD, Brasitus TA. Biochem Biophys Res Commun; 1994 Sep 30; 203(3):1432-7. PubMed ID: 7945291 [Abstract] [Full Text] [Related]
40. [Relation between the mitosis-inhibitory activity of a chalone preparation of Ehrlich ascites tumor and its diurnal secretion]. Bogoeva MV, Antokhin AI, Romanov IuA. Biull Eksp Biol Med; 1981 Mar 30; 91(3):343-5. PubMed ID: 6454450 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]